Chia Tai Tianqing’s PD-L1 Antibody Benmelstobart Wins NMPA Nod for ES-SCLC
China-based Chia Tai Tianqing has announced that it has received marketing approval from the National...
Company
GSK Shakes Up Leadership with Promotion of Cecilia Qi and Appointment of Sherman Yu
Mike Crichton, Senior Vice President of GlaxoSmithKline (GSK, NYSE: GSK) for the Greater China and...
Sichuan Biokin Pharmaceutical Advances BL-B16D1 to Clinical Trial for Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...
Bio-Thera Solutions’ PD-1 and ADC Combo Gets NMPA Approval for Clinical Trial in Solid Tumors
Bio-Thera Solutions, Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength
Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024,...
Jiangsu QYuns Therapeutics Gets NMPA Green Light for CSU Treatment QX013N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
MicroPort MedBot’s Toumai Robot Gets EU Green Light for Broad Surgical Applications
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its Toumai endoscopic surgery...
MicroPort CardioFlow Medtech’s AltaValve Receives FDA Breakthrough Designation for Mitral Regurgitation Treatment
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...
Laekna’s ActRIIA Monoclonal Antibody LAE102 Gets Green Light from China’s CDE for Obesity Treatment
Sino-US biotech firm Laekna has announced that it has received clinical trial approval from the...
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the...
Astellas Invests USD 90 Million in New US Facility to Boost Research and Commercialization
Japanese pharmaceutical company Astellas Pharma Inc. (TYO: 4503) has inaugurated a state-of-the-art laboratory and office...
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in...
Zai Lab’s Q1 2024 Revenue Rises 43% YOY on Strong Product Launch and NRDL Inclusion
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first...
BeiGene’s Q1 2024 Revenue Jumps 68% YOY on Strength of Brukinsa and Tislelizumab Sales
BeiGene, Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...
Brii Biosciences’ BRII-835 Aims for Breakthrough Therapy Status in China for Chronic Hepatitis B
The Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...
Jiangsu Hengrui Pharmaceuticals Advances HRS-5965 with NMPA Clinical Trial Approval for Glomerular Diseases
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...
Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way
Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues...
Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Blue Sail Medical’s New Catheter Receives NMPA Approval for Complex Coronary Lesion Treatment
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has received marketing approval from the National...
Abbisko and Allist Pharmaceuticals Initiate Phase II Trial for NSCLC Drug Combination
Abbisko Therapeutics Co., Ltd (HKG: 2256) and Allist Pharmaceuticals Co., Ltd have announced the upcoming...